Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/SRPK2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/SRPK2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/SRPK2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/SRPK2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SRPK2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SRPK2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/SRPK2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SRPK2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SRPK2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SRPK2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SRPK2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001905829 | Skin | cSCC | viral life cycle | 157/4864 | 317/18723 | 1.29e-19 | 1.88e-17 | 157 |
GO:004802428 | Skin | cSCC | regulation of mRNA splicing, via spliceosome | 67/4864 | 101/18723 | 1.83e-17 | 1.98e-15 | 67 |
GO:0019079112 | Skin | cSCC | viral genome replication | 76/4864 | 131/18723 | 7.80e-15 | 5.76e-13 | 76 |
GO:0048524111 | Skin | cSCC | positive regulation of viral process | 40/4864 | 65/18723 | 1.60e-09 | 5.97e-08 | 40 |
GO:0050792112 | Skin | cSCC | regulation of viral process | 77/4864 | 164/18723 | 5.38e-09 | 1.78e-07 | 77 |
GO:0045069111 | Skin | cSCC | regulation of viral genome replication | 46/4864 | 85/18723 | 3.08e-08 | 8.30e-07 | 46 |
GO:1903900112 | Skin | cSCC | regulation of viral life cycle | 68/4864 | 148/18723 | 1.17e-07 | 2.77e-06 | 68 |
GO:000626012 | Skin | cSCC | DNA replication | 106/4864 | 260/18723 | 1.18e-07 | 2.77e-06 | 106 |
GO:00069976 | Skin | cSCC | nucleus organization | 62/4864 | 133/18723 | 2.21e-07 | 4.72e-06 | 62 |
GO:00002458 | Skin | cSCC | spliceosomal complex assembly | 42/4864 | 79/18723 | 2.35e-07 | 4.99e-06 | 42 |
GO:004507016 | Skin | cSCC | positive regulation of viral genome replication | 21/4864 | 30/18723 | 5.52e-07 | 1.06e-05 | 21 |
GO:004578717 | Skin | cSCC | positive regulation of cell cycle | 120/4864 | 313/18723 | 8.95e-07 | 1.64e-05 | 120 |
GO:007099729 | Skin | cSCC | neuron death | 133/4864 | 361/18723 | 2.91e-06 | 4.58e-05 | 133 |
GO:190121627 | Skin | cSCC | positive regulation of neuron death | 42/4864 | 97/18723 | 1.56e-04 | 1.37e-03 | 42 |
GO:190121426 | Skin | cSCC | regulation of neuron death | 112/4864 | 319/18723 | 1.71e-04 | 1.48e-03 | 112 |
GO:00450719 | Skin | cSCC | negative regulation of viral genome replication | 27/4864 | 56/18723 | 2.84e-04 | 2.27e-03 | 27 |
GO:005140225 | Skin | cSCC | neuron apoptotic process | 88/4864 | 246/18723 | 4.04e-04 | 3.16e-03 | 88 |
GO:0043525111 | Skin | cSCC | positive regulation of neuron apoptotic process | 27/4864 | 58/18723 | 5.74e-04 | 4.18e-03 | 27 |
GO:004852517 | Skin | cSCC | negative regulation of viral process | 37/4864 | 92/18723 | 1.94e-03 | 1.17e-02 | 37 |
GO:001820923 | Skin | cSCC | peptidyl-serine modification | 108/4864 | 338/18723 | 7.73e-03 | 3.60e-02 | 108 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SRPK2 | SNV | Missense_Mutation | novel | c.736N>A | p.Glu246Lys | p.E246K | P78362 | protein_coding | deleterious(0.02) | probably_damaging(0.986) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
SRPK2 | SNV | Missense_Mutation | | c.536N>C | p.Val179Ala | p.V179A | P78362 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SRPK2 | SNV | Missense_Mutation | | c.406N>A | p.Glu136Lys | p.E136K | P78362 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
SRPK2 | insertion | Frame_Shift_Ins | novel | c.1735_1736insTAGAGAGTGCTGTGTGGAGA | p.Trp579LeufsTer39 | p.W579Lfs*39 | P78362 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SRPK2 | insertion | Nonsense_Mutation | novel | c.964_965insATTGAATGTAAGTTGCCTTGGTCATCACAATCCATGTAAAGGAG | p.Pro322HisfsTer2 | p.P322Hfs*2 | P78362 | protein_coding | | | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
SRPK2 | SNV | Missense_Mutation | | c.169N>C | p.Glu57Gln | p.E57Q | P78362 | protein_coding | deleterious(0.04) | probably_damaging(0.994) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SRPK2 | SNV | Missense_Mutation | | c.57G>T | p.Glu19Asp | p.E19D | P78362 | protein_coding | tolerated(0.33) | benign(0.388) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SRPK2 | SNV | Missense_Mutation | | c.277N>T | p.His93Tyr | p.H93Y | P78362 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SRPK2 | SNV | Missense_Mutation | novel | c.766N>T | p.Pro256Ser | p.P256S | P78362 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SRPK2 | SNV | Missense_Mutation | | c.169N>C | p.Glu57Gln | p.E57Q | P78362 | protein_coding | deleterious(0.04) | probably_damaging(0.994) | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |